INT19235

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.14
First Reported 1982
Last Reported 2008
Negated 0
Speculated 1
Reported most in Abstract
Documents 11
Total Number 13
Disease Relevance 2.38
Pain Relevance 2.81

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (PDE1B) signal transduction (PDE1B) nucleolus (PDE1B)
nucleus (PDE1B) cytoplasm (PDE1B)
Anatomy Link Frequency
liver 1
smooth muscle 1
PDE1B (Homo sapiens)
Pain Link Frequency Relevance Heat
Morphine 15 99.98 Very High Very High Very High
long-term potentiation 123 99.70 Very High Very High Very High
adenocard 5 98.60 Very High Very High Very High
cINOD 5 98.48 Very High Very High Very High
agonist 3 98.36 Very High Very High Very High
opioid receptor 6 98.12 Very High Very High Very High
Catecholamine 1 97.68 Very High Very High Very High
aspirin 4 97.12 Very High Very High Very High
Neurotransmitter 25 94.48 High High
depression 17 90.44 High High
Disease Link Frequency Relevance Heat
Cognitive Disorder 195 99.44 Very High Very High Very High
Targeted Disruption 37 98.48 Very High Very High Very High
Infection 1 92.12 High High
Acquired Immune Deficiency Syndrome Or Hiv Infection 1 91.72 High High
Depression 17 90.44 High High
Schizophrenia 12 89.80 High High
Disease 48 89.20 High High
Neurodegenerative Disease 22 86.96 High High
Hyperplasia 2 84.16 Quite High
Hypertrophy 1 83.52 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In most cells and tissues, the capacity for hydrolysis of cyclic nucleotides by PDEs is an order of magnitude greater than the maximum rate of synthesis of cAMP and cGMP and thus small reductions in the activity of PDEs can produce large increases in the level of cyclic nucleotides and significant changes in the activity of cAMP-dependent protein kinase.
Negative_regulation (reductions) of PDEs
1) Confidence 0.14 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 0.37 Pain Relevance 0.06
No unambiguous correlation between the inhibition of mucosal PDEs and clinically observed gastric irritation was found.
Negative_regulation (inhibition) of PDEs
2) Confidence 0.10 Published 1982 Journal Agents Actions Section Abstract Doc Link 6295110 Disease Relevance 0.07 Pain Relevance 0.29
However, the inhibition of PDEs may modulate gastric side-effects of NSAIDs.
Negative_regulation (inhibition) of PDEs associated with cinod
3) Confidence 0.10 Published 1982 Journal Agents Actions Section Abstract Doc Link 6295110 Disease Relevance 0.07 Pain Relevance 0.30
These results indicate that glycycoumarin has an inhibitory effect on smooth muscle contraction induced by various types of stimulants through the inhibition of PDEs, especially isozyme 3, followed by the accumulation of intracellular cAMP.
Negative_regulation (inhibition) of PDEs in smooth muscle
4) Confidence 0.10 Published 2006 Journal J Ethnopharmacol Section Abstract Doc Link 16387459 Disease Relevance 0 Pain Relevance 0.03
Furthermore, pretreatment with glycycoumarin enhanced the relaxation induced by forskolin on CCh-evoked contraction, similar to that by pretreatment with IBMX, a non-specific inhibitor of phosphodiesterases (PDEs).
Negative_regulation (inhibitor) of PDEs
5) Confidence 0.10 Published 2006 Journal J Ethnopharmacol Section Abstract Doc Link 16387459 Disease Relevance 0.06 Pain Relevance 0.10
The few existing studies that investigated the effects of PDE-Is on LTP indicate that inhibition of PDEs may have a beneficial effect on synaptic plasticity.
Negative_regulation (inhibition) of PDEs associated with long-term potentiation
6) Confidence 0.04 Published 2008 Journal Psychopharmacology (Berl) Section Body Doc Link PMC2704616 Disease Relevance 0.21 Pain Relevance 0.64
Using zero co-mentions as a cutoff is a convenience to avoid this problem even if the end result is that some relationships are declared "known" when they really are not.
Negative_regulation (declared) of known
7) Confidence 0.03 Published 2004 Journal BMC Bioinformatics Section Body Doc Link PMC526381 Disease Relevance 0.06 Pain Relevance 0
Inhibition of PDEs increases the intracellular availability of the second messengers cGMP and/or cAMP.


Negative_regulation (Inhibition) of PDEs
8) Confidence 0.02 Published 2008 Journal Psychopharmacology (Berl) Section Abstract Doc Link PMC2704616 Disease Relevance 0.99 Pain Relevance 0.15
This study was undertaken to determine whether isozyme-specific inhibitors of cAMP-selective phosphodiesterases (PDEs) induce bronchodilation without the cardiovascular side effects known to be produced by nonselective PDE inhibitors.
Spec (whether) Negative_regulation (inhibitors) of PDEs
9) Confidence 0.01 Published 1991 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 2033517 Disease Relevance 0.05 Pain Relevance 0.04
Indeed, Sutherland and colleagues discovered that glucagon and catecholamines act in the liver by increasing the concentrations of cAMP and that the effect of caffeine on glucagon involved the inhibition of cAMP-dependent PDEs (Berthet et al 1957; Rall and Sutherland 1958; Butcher and Sutherland 1962; Exton et al 1971).
Negative_regulation (inhibition) of PDEs in liver associated with catecholamine
10) Confidence 0.01 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2518390 Disease Relevance 0 Pain Relevance 0.09
An increase of cyclic adenosine and guanosine monophosphate (cAMP and cGMP) level can be achieved by inhibition of phosphodiesterases (PDEs), which are the enzymes responsible for the conversion of these second messengers into the corresponding 5-monophosphate inactive counterparts.
Negative_regulation (inhibition) of PDEs associated with adenocard
11) Confidence 0.01 Published 2000 Journal Eur J Med Chem Section Abstract Doc Link 10889326 Disease Relevance 0.14 Pain Relevance 0.11
The antibodies inhibited basal and PGE1-stimulated cAMP levels, and mimicked the effect of agonists manifest in a compensatory increase in cAMP formation.
Negative_regulation (inhibited) of PGE1-stimulated associated with agonist
12) Confidence 0.00 Published 1999 Journal FEBS Lett. Section Abstract Doc Link 10452543 Disease Relevance 0 Pain Relevance 0.21
Our results show that morphine inhibited anti-CD3/CD28-stimulated IFN-gamma promoter activity in a dose-dependent manner.
Negative_regulation (inhibited) of CD28-stimulated associated with morphine
13) Confidence 0.00 Published 2003 Journal J. Biol. Chem. Section Abstract Doc Link 12842891 Disease Relevance 0.35 Pain Relevance 0.78

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox